{"id":40473,"date":"2021-05-03T07:25:58","date_gmt":"2021-05-03T07:25:58","guid":{"rendered":"https:\/\/i-base.info\/htb\/?p=40473"},"modified":"2021-05-03T21:57:47","modified_gmt":"2021-05-03T21:57:47","slug":"interim-results-report-80-efficacy-for-indias-covaxin-vaccine","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/40473","title":{"rendered":"Interim results report 80% efficacy for India\u2019s COVAXIN vaccine"},"content":{"rendered":"
\n

<\/span>Simon Collins, HIV i-Base<\/strong><\/p>\n<\/div>\n

\n

Against a background of rapid and dramatic increases in COVID-19 cases and mortality in India, the country\u2019s vaccine programme includes the COVAXIN vaccine developed by Bharat Biotech in collaboration with the Indian Council of Medical Research.<\/span><\/strong><\/p>\n<\/div>\n

\n

COVAXIN is an adjuvanted whole inactivated SARS-COV-2 vaccine (BBV152) that is given as two doses four weeks apart. <\/span><\/p>\n<\/div>\n

\n

Results from randomised double-blind phase 2 study and earlier immunogenicity and safety data are both published in Lancet Infectious Diseases. [1, 2]<\/span><\/p>\n<\/div>\n

\n

Clinical results from an interim analysis of a phase 3 study have so far only reported in a company press release. The study enrolled >25,000 participants, approximately 10% > 60 years old. \u00a0Top line results include 80% efficacy at reducing PCR-confirmed symptomatic COVID-19 (7 vs 36 cases). The study will continue until reaching planned 130 endpoints. \u00a0[3]<\/span><\/p>\n<\/div>\n

\n

References<\/p>\n<\/div>\n

\n
    \n
  1. Ella R et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial. DOI: 10.1016\/S1473-3099(21)00070-0. (8 March 2021).
    \n<\/span>https:\/\/www.thelancet.com\/journals\/laninf\/article\/PIIS1473-3099(21)00070-0\/fulltext<\/a><\/li>\n
  2. Ella R et al. Evaluation of safety and immunogenicity of an adjuvanted, TH-1 skewed, whole virion inactivated SARS-CoV-2 vaccine – BBV152. Lancet Inf Dis. DOI: 10.1016\/S1473-3099(20)30942-7 (21 January 2021).
    \n    https:\/\/www.thelancet.com\/journals\/laninf\/article\/PIIS1473-3099(20)30942-7\/fulltext<\/a><\/span><\/li>\n
  3. Bharat Biotech press release. Bharat Biotech announces phase 3 results of COVAXIN: India\u2019s first COVID-19 vaccine demonstrates interim clinical efficacy of 81%. (3 March 2021).
    \n    https:\/\/www.bharatbiotech.com\/images\/press\/covaxin-phase3-efficacy-results.pdf<\/a> (PDF)<\/li>\n<\/ol>\n

    This report was first published on 23 April 2021.<\/em><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

    Simon Collins, HIV i-Base Against a background of rapid and dramatic increases in COVID-19 cases and mortality in India, the country\u2019s vaccine programme includes the COVAXIN vaccine developed by Bharat Biotech in collaboration with the Indian Council of Medical Research. …<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[292,278],"tags":[],"class_list":["post-40473","post","type-post","status-publish","format-standard","hentry","category-covid-19-vaccine","category-covid-19"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/40473","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=40473"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/40473\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=40473"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=40473"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=40473"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}